| Literature DB >> 33800141 |
Samanta Salvi1, Erika Bandini1, Silvia Carloni1, Valentina Casadio1, Michela Battistelli2, Sara Salucci2, Ilaria Erani1, Emanuela Scarpi3, Roberta Gunelli4, Giacomo Cicchetti5, Michele Guescini2, Massimiliano Bonafè6, Francesco Fabbri1.
Abstract
Prostate Cancer (PCa) is one of the most frequently identified urological cancers. PCa patients are often over-diagnosed due to still not highly specific diagnostic methods. The need for more accurate diagnostic tools to prevent overestimated diagnosis and unnecessary treatment of patients with non-malignant conditions is clear, and new markers and methods are strongly desirable. Extracellular vesicles (EVs) hold great promises as liquid biopsy-based markers. Despite the biological and technical issues present in their detection and study, these particles can be found highly abundantly in the biofluid and encompass a wealth of macromolecules that have been reported to be related to many physiological and pathological processes, including cancer onset, metastasis spreading, and treatment resistance. The present study aims to perform a technical feasibility study to develop a new workflow for investigating EVs from several biological sources. Serum and urinary supernatant EVs of PCa, benign prostatic hyperplasia (BPH) patients, and healthy donors were isolated and investigated by a fast, easily performable, and cost-effective cytofluorimetric approach for a multiplex detection of 37 EV-antigens. We also observed significant alterations in serum and urinary supernatant EVs potentially related to BPH and PCa, suggesting a potential clinical application of this workflow.Entities:
Keywords: MACSPlex Exosome kit; extracellular vesicles; prostate cancer; serum; urine
Year: 2021 PMID: 33800141 PMCID: PMC7998238 DOI: 10.3390/diagnostics11030466
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418